查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1074804

全球疫苗佐剂市场：按类型、产品、疾病类型、区域预测分析（~ 2028 年）

Vaccine Adjuvants Market Forecasts to 2028 - Global Analysis By Type (Virus-like Particles, Tensoactive Adjuvants, Organic Adjuvants), Product (Adjuvant Emulsions, Combination Adjuvants), Disease Type (Cancer, Infectious Diseases) and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

预计2021年全球疫苗佐剂市场规模将达到7.91亿美元，预测期内復合年增长率为14.5%，2028年达到20.4087亿美元。

本报告调查和分析全球疫苗佐剂市场、市场促进者、抑制者、类型、产品、疾病类型、作用机制、给药途径、用途、最终用户、区域市场分析和公司概况。提供有关信息。

目录

第 1 章执行摘要

第2章前言

第三章市场趋势分析

  • 促进因素
  • 抑制器
  • 市场机会
  • 威胁
  • 产品分析
  • 使用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第四章波特五力分析

第 5 章全球疫苗佐剂市场：按类型

    它是
  • 病毒样颗粒
  • Tenso 活性佐剂
  • 有机助剂
  • 矿物盐佐剂
  • 脂质体
  • 乳液
  • 碳水化合物佐剂
  • 菌剂

第 6 章全球疫苗佐剂市场：按产品分类

  • 佐剂乳液
  • 联合佐剂
  • 颗粒佐剂
  • 病原体成分
  • 皂□

第 7 章全球疫苗佐剂市场：按疾病类型

  • 癌症
  • 传染病

第 8 章全球疫苗辅助市场：按作用机制

  • 车辆助剂
  • 运营商
  • 活性免疫刺激剂

第 9 章全球疫苗辅助市场：按管理途径

  • 皮下途径
  • 口服途径
  • 鼻内途径
  • 肌内途径
  • 皮内通路

第 10 章全球疫苗佐剂市场：按应用分类

  • 动物用疫苗佐剂
  • 人用疫苗佐剂

第 11 章全球疫苗助手市场：按最终用户分类

  • 研究机构
  • 製药公司
  • 合同製造组织
  • 商业
  • 儿童
  • 成人

第 12 章全球疫苗佐剂市场：按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东/非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东/非洲

第13章主要发展

  • 合同、伙伴关係、合作、合资企业
  • 收购兼併
  • 推出新产品
  • 业务拓展
  • 其他重要策略

第 14 章公司简介

  • Adjuvance Technologies, Inc
  • Adjuvatis
  • Agenus, Inc.
  • Aphios Corp.
  • Avanti Polar Lipids
  • CSL Limited
  • CureVac AG
  • GSK
  • Invivogen
  • Kineta, Inc.
  • MVP Laboratories, Inc.
  • Novartis/CSL
  • Novavax, Inc.
  • OZ Biosciences
  • Sergeant Adjuvants
  • Sigma Aldrich(Merck KGaA)
  • Vaxine Pty Ltd.
  • Vaxliant
  • Viscogel AB
  • Sanofi
  • SK bioscience
Product Code: SMRC21403

According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $791.00 million in 2021 and is expected to reach $2,040.87 million by 2028 growing at a CAGR of 14.5% during the forecast period. Adjuvants are fundamentally compounds that improve the body's immunogenic reaction against antigens. As a result, these are majorly added to vaccines to increase their capability to influence long-term protection and safety against any kind of viruses. Currently, MF59 and aluminum salts are the only adjuvants which are viable for human usage. There have been a lot of developments done on the antigen discovery over the past decade which has enhanced the vaccine development process.

Market Dynamics:

Driver:

Rising Incidence of Naive Infectious Chronic Diseases

The upsurge in the prevalence of cervical cancer, infectious diseases like Human Papillomavirus (HPV), HIV, tuberculosis, etc., and other fatal diseases are predicted to drive the market. Moreover, in recent years there has been an increasing focus on developing more efficient and longer-lasting vaccination against current and new diseases. The current onset of the Covid-19 pandemic is expected to create massive growth opportunities for the development of the global market. The research and development activities for creating a vaccine for Covid-19 have been underway at full force. With over a million cases across the globe and more than 160 countries affected, it has become imperative to find a vaccine for the infection. This will present a promising demand for the overall development of the market.

Restraint:

High Cost of Raw material

The increasing costs of the raw materials which in turn have lifted the cost of manufacturing are a few of the factors hindering the growth of the market. The cost of developing new vaccine adjuvants, the high toxicity of adjuvants on application, huge investment required for developing a new adjuvant, and strict regulatory requirements are some restraining factors that are expected to hamper the global vaccine adjuvants market growth.

Opportunity:

Increasing Research & Development

Increased levels of spending and funding allocated for the development of more efficient vaccine adjuvants. The regional segment of Western Europe and the APEJ segment is next in line after North America in terms of revenue generation. Increasing government initiatives for vaccinations and the high prevalence of infectious & zoonotic diseases are accelerating the growth of the market. An increasing technological advancement focusing on improved & long-lasting vaccines for existing and emerging chronic diseases is creating ample opportunity for the market.

Threat:

Side Effects

Adjuvanted vaccines can cause more local reactions (such as redness, swelling, and pain at the injection site) and more systemic reactions (such as fever, chills, and body aches) than non-adjuvanted vaccines. Side effects of adjuvants will further derail the market growth rate. The high manufacturing cost of these drugs will also create hindrances to the growth of this market.

Particulate Adjuvants segment is expected to be the largest during the forecast period

The Particulate segment is expected to hold the largest market share while adjuvant emulsion segment is predicted to grow with the highest CAGR. The factors can be attributed to the growing prevalence of diseases such as allergy, cancer, & HIV/AIDS, development of improved vaccine immunization, and rising demand for advanced treatment options.

The Intramuscular Route segment is expected to have the highest CAGR during the forecast period

The intramuscular Route segment is driven by owing to rapidly rising geriatric population and vaccines for enhanced immunization are propelling the growth of this segment. These include vaccines for HPV, influenza, meningitis, etc.

Region with highest share:

The Asia Pacific is projected to hold the highest market share. The growth in this market cantered at China and India. Increasing incidence of infectious diseases, rising number of conferences and symposiums, and high growth in the Indian biotechnology sector are the major factors driving the market in the Asian province. Moreover, the continuously improving healthcare facilities such as the availability of medicines, coupled with the increase in research & development funding to meet the huge unmet demands. This is expected to increase the market share over the forecast period.

Region with highest CAGR:

North America is projected to have the highest CAGR, owing to high adoption of the innovative products and incidence of major market players in this province especially in the United States. Further, favourable government support towards the growth of healthcare infrastructure is also contributing the growth of the vaccine adjuvants market in this region.

Key players in the market:

Some of the key players profiled in the Vaccine Adjuvants Market include Adjuvance Technologies, Inc, Adjuvatis, Agenus, Inc, Aphios Corp, Avanti Polar Lipids, CSL Limited, CureVac AG, GSK, Invivogen, Kineta, Inc, MVP Laboratories, Inc, Novartis/CSL, Novavax, Inc, OZ Biosciences, Sergeant Adjuvants, Sigma Aldrich (Merck KGaA), Vaxine Pty Ltd, Vaxliant, Viscogel AB, Sanofi, SK bioscience.

Key developments:

In February 2022: Sanofi and GSK intends to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.

In August 2021: SK bioscience and GlaxoSmithKline plc (GSK) initiated a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination with GSK's pandemic adjuvant following positive interim Phase 1/2 results..

Types Covered:

  • Virus-like Particles
  • Tensoactive Adjuvants
  • Organic Adjuvants
  • Mineral Salt based Adjuvants
  • Liposomes
  • Emulsions
  • Carbohydrates Adjuvants
  • Bacteria-derived Adjuvants

Products Covered:

  • Adjuvant Emulsions
  • Combination Adjuvants
  • Particulate Adjuvants
  • Pathogen Components
  • Saponin

Disease Types Covered:

  • Cancer
  • Infectious Diseases

Mechanism of Actions Covered:

  • Vehicle Adjuvants
  • Carriers
  • Active Immunostimulants

Route of Administrations Covered:

  • Subcutaneous Route
  • Oral Route
  • Intranasal Route
  • Intramuscular Route
  • Intradermal Route

Applications Covered:

  • Veterinary Vaccine Adjuvants
  • Human Vaccine Adjuvants

End Users Covered:

  • Research Institutes
  • Pharmaceutical Companies
  • Contract Manufacturing Organization
  • Commercial
  • Pediatric
  • Adults

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025 and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaccine Adjuvants Market, By Type

  • 5.1 Introduction
  • 5.2 Virus-like Particles
  • 5.3 Tensoactive Adjuvants
  • 5.4 Organic Adjuvants
  • 5.5 Mineral Salt based Adjuvants
  • 5.6 Liposomes
  • 5.7 Emulsions
  • 5.8 Carbohydrates Adjuvants
  • 5.9 Bacteria-derived Adjuvants

6 Global Vaccine Adjuvants Market, By Product

  • 6.1 Introduction
  • 6.2 Adjuvant Emulsions
  • 6.3 Combination Adjuvants
  • 6.4 Particulate Adjuvants
  • 6.5 Pathogen Components
  • 6.6 Saponin

7 Global Vaccine Adjuvants Market, By Disease Type

  • 7.1 Introduction
  • 7.2 Cancer
  • 7.3 Infectious Diseases

8 Global Vaccine Adjuvants Market, By Mechanism of Action

  • 8.1 Introduction
  • 8.2 Vehicle Adjuvants
  • 8.3 Carriers
  • 8.4 Active Immunostimulants

9 Global Vaccine Adjuvants Market, By Route of Administration

  • 9.1 Introduction
  • 9.2 Subcutaneous Route
  • 9.3 Oral Route
  • 9.4 Intranasal Route
  • 9.5 Intramuscular Route
  • 9.6 Intradermal Route

10 Global Vaccine Adjuvants Market, By Application

  • 10.1 Introduction
  • 10.2 Veterinary Vaccine Adjuvants
  • 10.3 Human Vaccine Adjuvants

11 Global Vaccine Adjuvants Market, By End User

  • 11.1 Introduction
  • 11.2 Research Institutes
  • 11.3 Pharmaceutical Companies
  • 11.4 Contract Manufacturing Organization
  • 11.5 Commercial
  • 11.6 Pediatric
  • 11.7 Adults

12 Global Vaccine Adjuvants Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Adjuvance Technologies, Inc
  • 14.2 Adjuvatis
  • 14.3 Agenus, Inc.
  • 14.4 Aphios Corp.
  • 14.5 Avanti Polar Lipids
  • 14.6 CSL Limited
  • 14.7 CureVac AG
  • 14.8 GSK
  • 14.9 Invivogen
  • 14.10 Kineta, Inc.
  • 14.11 MVP Laboratories, Inc.
  • 14.12 Novartis/CSL
  • 14.13 Novavax, Inc.
  • 14.14 OZ Biosciences
  • 14.15 Sergeant Adjuvants
  • 14.16 Sigma Aldrich (Merck KGaA)
  • 14.17 Vaxine Pty Ltd.
  • 14.18 Vaxliant
  • 14.19 Viscogel AB
  • 14.20 Sanofi
  • 14.21 SK bioscience

List of Tables

  • Table 1 Global Vaccine Adjuvants Market Outlook, By Region (2020-2028) (US $MN)
  • Table 2 Global Vaccine Adjuvants Market Outlook, By Type (2020-2028) (US $MN)
  • Table 3 Global Vaccine Adjuvants Market Outlook, By Virus-like Particles (2020-2028) (US $MN)
  • Table 4 Global Vaccine Adjuvants Market Outlook, By Tensoactive Adjuvants (2020-2028) (US $MN)
  • Table 5 Global Vaccine Adjuvants Market Outlook, By Organic Adjuvants (2020-2028) (US $MN)
  • Table 6 Global Vaccine Adjuvants Market Outlook, By Mineral Salt based Adjuvants (2020-2028) (US $MN)
  • Table 8 Global Vaccine Adjuvants Market Outlook, By Liposomesm(2020-2028) (US $MN)
  • Table 9 Global Vaccine Adjuvants Market Outlook, By Emulsions (2020-2028) (US $MN)
  • Table 10 Global Vaccine Adjuvants Market Outlook, By Carbohydrates Adjuvants (2020-2028) (US $MN)
  • Table 11 Global Vaccine Adjuvants Market Outlook, By Bacteria-derived Adjuvants (2020-2028) (US $MN)
  • Table 12 Global Vaccine Adjuvants Market Outlook, By Product (2020-2028) (US $MN)
  • Table 13 Global Vaccine Adjuvants Market Outlook, By Adjuvant Emulsions (2020-2028) (US $MN)
  • Table 14 Global Vaccine Adjuvants Market Outlook, By Combination Adjuvants (2020-2028) (US $MN)
  • Table 15 Global Vaccine Adjuvants Market Outlook, By Particulate Adjuvants (2020-2028) (US $MN)
  • Table 16 Global Vaccine Adjuvants Market Outlook, By Pathogen Components (2020-2028) (US $MN)
  • Table 17 Global Vaccine Adjuvants Market Outlook, By Saponin (2020-2028) (US $MN)

Table18 Global Vaccine Adjuvants Market Outlook, By Disease Type (2020-2028) (US $MN)

  • Table 19 Global Vaccine Adjuvants Market Outlook, By Cancer (2020-2028) (US $MN)
  • Table 20 Global Vaccine Adjuvants Market Outlook, By Infectious Diseases (2020-2028) (US $MN)
  • Table 21 Global Vaccine Adjuvants Market Outlook, By Mechanism of Action (2020-2028) (US $MN)
  • Table 22 Global Vaccine Adjuvants Market Outlook, By Vehicle Adjuvants (2020-2028) (US $MN)
  • Table 23 Global Vaccine Adjuvants Market Outlook, By Carriers (2020-2028) (US $MN)
  • Table 24 Global Vaccine Adjuvants Market Outlook, By Active Immunostimulants (2020-2028) (US $MN)
  • Table 25 Global Vaccine Adjuvants Market Outlook, By Route of Administration (2020-2028) (US $MN)
  • Table 26 Global Vaccine Adjuvants Market Outlook, By Subcutaneous Route (2020-2028) (US $MN)
  • Table 27 Global Vaccine Adjuvants Market Outlook, By Oral Route (2020-2028) (US $MN)
  • Table 28 Global Vaccine Adjuvants Market Outlook, By Intranasal Route (2020-2028) (US $MN)
  • Table 29 Global Vaccine Adjuvants Market Outlook, By Intramuscular Route (2020-2028) (US $MN)
  • Table 30 Global Vaccine Adjuvants Market Outlook, By Intradermal Route (2020-2028) (US $MN)
  • Table 31 Global Vaccine Adjuvants Market Outlook, By Application (2020-2028) (US $MN)
  • Table 32 Global Vaccine Adjuvants Market Outlook, By Veterinary Vaccine Adjuvants (2020-2028) (US $MN)
  • Table 33 Global Vaccine Adjuvants Market Outlook, By Human Vaccine Adjuvants (2020-2028) (US $MN)
  • Table 34 Global Vaccine Adjuvants Market Outlook, By End User (2020-2028) (US $MN)
  • Table 35 Global Vaccine Adjuvants Market Outlook, By Research Institutes (2020-2028) (US $MN)
  • Table 36 Global Vaccine Adjuvants Market Outlook, By Pharmaceutical Companies (2020-2028) (US $MN)
  • Table 37 Global Vaccine Adjuvants Market Outlook, By Contract Manufacturing Organization (2020-2028) (US $MN)
  • Table 38 Global Vaccine Adjuvants Market Outlook, By Commercial (2020-2028) (US $MN)
  • Table 39 Global Vaccine Adjuvants Market Outlook, By Pediatric (2020-2028) (US $MN)
  • Table 40 Global Vaccine Adjuvants Market Outlook, By Adults (2020-2028) (US $MN)

Note- Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.